Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.39 |
| ▸ | TUBB | P07437 | 3/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21614310 | 0.81 | POLB (0.44) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29514108 | 0.80 | ALOX5AP (0.40) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL1519286 | 0.80 | ALOX5AP (0.40) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL4922559 | 0.79 | CA2 (0.44) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL14725631 | 0.77 | NQO2 (0.40) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL9213947 | 0.77 | CA2 (0.43) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL10700601 | 0.77 | POLB (0.46) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL24638792 | 0.77 | ALOX5AP (0.45) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL26654810 | 0.77 | EP300 (0.39) | ALOX5APFEN1TUBB1TUBB4ATUBB | |
| SCHEMBL127769 | 0.75 | CA2 (0.55) | ALOX5APFEN1TUBB1TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116648453-A | 5-and 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 活力疗法公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4225742-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230065635-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
| US-20230065635-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | ALOX5AP 2801/4885FEN1 4071/4885TUBB1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.